Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode

NCT00145509 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT00145509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2005
Completion date
December 31, 2007
Enrollment
77 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder